East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class ...

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

The accelerated approval of iptacopan for IgAN was based on a reduction in proteinuria observed in the APPLAUSE-IgAN trial. The Food and Drug Administration (FDA) has granted accelerated approval to ...

--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- NovelMed is ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with iptacopan had a 38.3% reduction in proteinuria at 9 months. Iptacopan was well-tolerated ...

If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...

- Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 PASADENA, ...

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA ...